AJOVY® (fremanezumab) significantly reduced monthly migraine days (MMD) and monthly headache days (MHD) versus placebo over a 12-week period in pediatric patients aged 6-17 years1
Efficacy consi......
LAKE TAHOE, Nev., Dec. 03, 2024 (GLOBE NEWSWIRE) -- 2ONE Labs Inc., is pleased to have received 'Acceptance' of a second Premarket Tobacco Product Application (PMTA) for additional flavored 2ONE® n......
Collaboration intends to leverage proprietary AI technology from Philips and Mayo Clinic to target breakthroughs in ease-of-use and efficiency to bring high-quality diagnostic MRI ......
